We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.

Atlas Venture

OrbiMed

T. Rowe Price

Cystic Fibrosis Foundation

The Rise Fund

TPG Rise Climate Fund

RA Capital Management

Sionna Therapeutics

Managing a cystic fibrosis (#CF) diagnosis can be challenging. Jennifer, whose child is living with CF, has found ways to make the diagnosis less overwhelming. Read about her journey here: https://lnkd.in/dExcKR4g

At Sionna, we exercise our Core Values through our quarterly Culture Blasts. These events provide a way for us to come together regularly, learn about ourselves, practice our leadership skills and celebrate our achievements! 

During our most recent #CultureBlast in March, we had a great time celebrating our successful Series C financing and engaging in team bonding activities. Check out some pictures from the event!  

Just a few weeks after closing our Series C round, President & CEO Michael Cloonan reflected on the process of a private funding round and the key drivers of success including science, relationships and experience.  
 
Find the full post on the "From The Trenches" LifeSciVC blog organized by Bruce Booth of Atlas Venture: https://lnkd.in/es4mmfCz

We take calculated risks and purposefully explore creative ways to raise the bar for people living with cystic fibrosis (CF). In line with our core value of Intentional Innovation, Juliet Labadorf, Senior Director, Financial Planning & Analysis, shares a message about Sionna’s dynamic approach to CF therapeutic development.  

We are committed to the collective well-being of our entire team. That’s why we value flexibility, prioritize employee-driven ways of working, and offer policies designed to enhance work/life balance. 

Learn more about life at Sionna: https://lnkd.in/etdzEAVY 

CrUX Dataset

CrUX Top 50m

Vimeo

Chief Medical Officer

Charlotte McKee

Chief Scientific Officer

John Macor

Chief People Officer

Vanya Sagar

Vice President Information Technology

Andy Chu

Vice President Program, Portfolio & Operations

Meghan Bagshaw

Vice President, CMC

Michael Hewitt

Vice President - Preclinical Drug Safety

Alison Easter

Senior Director, Corporate Controller

Erica Iorio

Associate Director, Operations and Contracts

George Durrance

Business Management

George Topalov

Bruce Booth

Edd Fleming

Michael Cloonan

Joshua Resnick

Lucian Iancovici

Adam Rosenberg

Peter Thompson

Greg Hurlbut

Co-Founder and SVP Head of Research

Mark Munson

Co-Founder and Vice President of Medicinal Chemistry

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Massachusetts Companies With Fewer Than 1000 Employees (Top 10K)

Massachusetts Companies With More Than 10 Employees (Top 10K)

East Coast Companies With Fewer Than 1000 Employees (Top 10K)

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function.

In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Enavate Sciences

Series C - Sionna Therapeutics

Series B - Sionna Therapeutics

Natick

Massachusetts

United States

North America

Sionna Therapeutics Announces Appointment of Laurie Stelzer to its Board of Directors

Cystic fibrosis: Five biotechs breathing life into the therapeutic space

Sionna Therapeutics expands pipeline via AbbVie deal

Sionna salvages AbbVie assets, teeing up dual combo assault on cystic fibrosis

Sionna Therapeutics on LinkedIn: #cf #cftr

The 10 Biggest Rounds Of March: Wonder, Biotech Headline Big Month

Sionna Therapeutics on LinkedIn: Just a few weeks after closing our Series C round, President & CEO Michael…

Sionna Therapeutics: $182 Million Funding Raised To Develop Novel Small Molecules In Cystic Fibrosis

The Week’s 10 Biggest Funding Rounds: Alumis Leads Big Biotech Week

A small molecule NBD1 stabilizer in Phase 1 clinical trials designed to restore CFTR function by stabilizing the NBD1 domain of the CFTR protein.

A small molecule targeting the interface between the ICL4 region and the NBD1 domain of the CFTR protein, currently in Phase 1 clinical trials.

A second series NBD1 stabilizer in preclinical development, designed to restore CFTR function by stabilizing the NBD1 domain.

India

Asia

Bangladesh

Mexico

Vertex Pharmaceuticals is a leading biotechnology company that has marketed medicines for cystic fibrosis.

Vertex Pharmaceuticals

Mediar Therapeutics is a competitor of Sionna Therapeutics in the development of cystic fibrosis therapies.

Mediar Therapeutics

Pliant is a competitor of Sionna Therapeutics in the field of cystic fibrosis therapies.

Pliant

Alentis Therapeutics is a competitor of Sionna Therapeutics in the development of therapies for cystic fibrosis.

Alentis Therapeutics

Blade Therapeutics competes with Sionna Therapeutics in the field of cystic fibrosis therapies.

Blade Therapeutics

Reneo Pharmaceuticals is a competitor of Sionna Therapeutics in the field of cystic fibrosis therapies.

Reneo Pharmaceuticals

Arcturus Therapeutics competes with Sionna Therapeutics in the field of cystic fibrosis therapies.

Arcturus Therapeutics

A biotechnology company focused on developing therapies to fully normalize CFTR function, targeting the NBD1, ICL4, and TMD1 regions of CFTR to achieve best-in-class efficacy for patients with cystic fibrosis.

Co-founder and SVP Head of Research

Head Protein Conformational Diseases Research

Head Rare Pulmonary Research - RD Director/Associate Director/Senior Principal Scientist

Senior Scientist / Staff Scientist II / Staff Scientist

Adjunct Faculty - Graduate School of Biomedical Sciences

Post Doctoral Fellow

Ph.D. Student

Co-founder and SVP Head of Research - Sionna Therapeutics

Senior Director Data Management

Director Data Management

Director Data Management and Programming

Associate Director Data Management

Manager Data Management

Senior Director Data Management, Sionna Therapeutics

Jamie Kistner

Senior Director of Financial Planning & Analysis

Director of Financial Planning & Analysis

Associate Director, Corporate Finance

Senior Manager, Financial Planning & Analysis

Manager, FP&A

Financial Analyst, FP&A

Senior in Distribution Operations & Reporting

Distribution Operations & Reporting

Audit Senior Assistant

Audit & Assurance Intern

Senior Director of Corporate Finance

Juliet Labadorf

Director

Associate Director

Senior Principal Scientist

Principal Scientist

Senior Scientist

Staff Scientist II

Staff Scientist I

Senior Research Chemist I

Senior Resear Chemist

Experienced Medicinal Chemist

Junkai Liao

Chief Financial Officer & Head of Corporate Development

Board Member

Executive Vice President, Chief Financial Officer

Senior Vice President, Investor Relations and Interim Chief Financial Officer

Senior Vice President, Investor Relations

Vice President, Investor Relations

Executive Director, Investor Relations

Chief Financial Officer & Head of Corporate Development, Sionna Therapeutics

Elena Ridloff

EVP, Chief Human Resources Officer

SVP, Head of Human Resources

VP, Head of Human Resources

HR Business Partner, R&D

HR Business Partner to CFO/Finance

Talent Acquisition Leader, R&D, PO&T, IT & CF

Administrative Director, Department of Neurology - Clinical Operations, Quality & Safety, Education

Director, Department of Neurology - Education and Training

Manager, Department of Neurology - Education Programs

Chief People Officer at Sionna Therapeutics

Director, Medicinal Chemistry

Senior Research Investigator

Preclinical Science Consultant

Research Investigator, Lead Optimization

Senior Research Scientist, Lead Optimization

Research Scientist, Medicinal Chemistry

Medicinal Chemist

Director of Clinical Operations

Associate Director of Clinical Operations

Associate Director, Clinical Operations Team Leader, US

Sr. Clinical Study Leader

Manager Clinical Operations

Clinical Trial Manager

Sr. Clinical Research Associate

Clinical Research Associate

Clinical Research Coordinator

Clinical Trial Coordinator I

Leasing Agent

Marketing Assistant

Director of Clinical Operations  at Sionna Therapeutics

Jessica Hauben

Chief Medical Officer at Sionna Therapeutics; Leadership Council, International Institute

VP, Cystic Fibrosis and AAT Clinical Development

VP Clinical Development

Vice President, Clinical Development and Medical Affairs

Senior Medical Director

Director, Experimental Medicine/Translational Research

Associate Director, Experimental Medicine

Fellow, Pulmonary and Critical Care Medicine

Intern and Resident, Internal Medicine

Associate Physician

Chief Medical Officer at Sionna Therapeutics; Leadership Council, International Institute of New England

news impact assignment basic	general	May 4, 2024 5:33 AM	20d49163
public peers	general	May 4, 2024 5:33 AM	da6c708e
news daily refresh	general	Sep 1, 2024 10:00 AM	66a16f11
news processing daily refresh	general	Sep 2, 2024 9:51 AM	04600232
news impact assignment daily	general	Sep 3, 2024 9:56 AM	56d394b0
news processing basic	general	May 4, 2024 5:33 AM	9cdbd552
company summary	general	Aug 25, 2024 5:46 PM	34342dcd
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	e2b33e6e
crunchbase profile	general	Nov 22, 2024 8:32 AM	7d7150b5
li profile	general	May 4, 2024 5:33 AM	f1daa1cb
translate crunchbase fundingrounds	general	Nov 22, 2024 8:50 AM	8727da98
peers	general
news basic	general	May 4, 2024 5:33 AM	f5f9e822
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SIONNATX

Sionna Therapeutics